Read Manning Fulton’s Updated Response to the Coronavirus (COVID-19) - Sept 17, 2020

Durham

Diamond View II, Suite 130, 280 South Mangum Street, Durham, NC 27701

(919) 787-8880 Contact

Raleigh

3605 Glenwood Avenue, Suite 500, Raleigh, NC 27612

(919) 787-8880 Contact

As published in The News & Observer:

Biotechnology company, Grifols, announced Wednesday that it has begun clinical trials for a COVID-19 treatment at its facility in Clayton, North Carolina.

Specifically, Grifols has entered into a partnership with the U.S. Biomedical Advanced Research Development Authority (BARDA) and the Food and Drug Administration (FDA) to harvest plasma — the water-based portion of blood that holds many proteins — from recovering COVID-19 patients and process it into a hyperimmune globulin.

The trials will determine if that hyperimmune globulin, which holds antibodies that fight things like viruses and bacteria, can be used to successfully treat COVID-19, the disease caused by the pandemic coronavirus.

Read more from The News & Observer here.

Grifols’ full March 25 press release, announcing its formal collaboration with the U.S. government to produce the first treatment specifically targeting COVID-19, may be read here.

Contact Us

Contact Us

Contact Us

Contact Us